natgillin/translations-raw huggingface dataset:
contains substantially no water in its composition (has a water content of less than 0.1%). 
u biti ne sadrži vodu u svom sastavu (ima sadržaj vode manji od 0,1%).
or a pharmaceutically acceptable salt, solvate, polymorph or stereoisomer thereof, comprising the step of cyclizing an N-(3-aminophthaloyl)-glutamine compound of Formula (II), an N-(3-aminophthaloyl)-isoglutamine compound of (IIA) or a salt thereof: 
(D, ili njegove farmaceutski prihvatljive soli, solvata, polimorfa ili stereoizomera, naznačen time što se sastoji u koraku reakcije 3-aminoftalne kiseline, ili njezine soli, sa spojem 3-aminoglutarimida Formule (X), ili njegovom solju:
An isolated antibody that can specifically bind to human Sp35 polypeptide (SEQ ID NO:2), wherein the antibody comprises the amino acid sequence set forth in SEQ ID NO:434 and the amino acid sequence set forth in SEQ ID NO: 435. The antibody of claim 1, wherein the heavy chain of the antibody comprises the amino acid sequence set forth in SEQ ID NO: 435. 
Izolirano protutijelo koje se može specifično vezati na ljudski polipeptid Sp35 (SEQ ID NO:2), naznačeno time što protutijelo sadrži aminokiselinski slijed iznijet u SEQ ID NO:434 1 aminokiselinski slijed iznijetu SEQ ID NO: Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što teški lanac protutijela sadrži aminokiselinski slijed iznijet u SEQ ID NO: 435.
for each of at least some of a plurality of ovens carried by each one of the plurality of vehicles, to determine at least one of a respective cooking temperature or cooking time to cook a respective content of the oven, based at least in part an estimated transit time for the respective vehicle to the respective one of the destinations to which the respective content of the oven is to be delivered; 
proizvodnju signala pomoću najmanje jedne upravljačke jedinice (102, 118), koji zaustavlja kuhanje sadržaja u štednjaku (210) kada je postignuto određeno vrijeme kuhanja za postavljene temperature na kojima je određeni štednjak radio za vrijeme barem dijela putovanja vozila (240), na temelju dinamički ažuriranog predviđenog vremena putovanja do dostavnog odredišta za dostavu sadržaja iz odgovarajućeg štednjaka.
A dental hand instrument of claim 1, wherein the connecting bore is aligned so as to be inclined with respect to a plane running perpendicularly to a longitudinal axis of the substantially cylindrical hollow space. 
Ručni zubarski instrument u skladu s patentnim zahtjevom 1, karakteriziran na način da je svrdlo za pričvršćivanje (10, 20) orijentirano pod nagibom u odnosu na ravninu koja prolazi okomito na uzdužnu os (I) šupljeg prostora (7).
The antibody for use according to claim 9, wherein the second therapeutic agent is a chemotherapeutic agent, and wherein optionally the chemotherapeutic agent is an antimetabolite chemotherapeutic agent, which antimetabolite chemotherapeutic agent is optionally gemcitabine. 
Pertuzumab za uporabu prema zahtjevu 5, naznačen time, da drugo terapeutsko sredstvo je kemoterapeutsko sredstvo. Pertuzumab za uporabu prema zahtjevu 6, naznačen time, da kemoterapeutsko sredstvo je antimetaboličko kemoterapeutsko sredstvo.
• means (30, 31, 33, 34) for translating the support means (10) with respect to said connection element (11) due to the tension of the cord (8); 
* elemente (30, 31, 33, 34) za pomicanje nosača (10) u odnosu na navedeni spojni element (11) zbog napinjanja užeta (8);
Mixing member for blenders The present invention relates to a mixing member for blenders. As is known, blenders are used for making home-made ice-cream, and normally comprise a cylindrical, horizontal-axis bowl into which the ingredients for producing a given quantity of ice-cream are poured; a cooling unit for cooling and maintaining the bowl and contents at a temperature ranging between -10°C and - 35°C; and a rotary mixing member mounted for rotation inside the bowl to blend the ingredients at the various ice-cream-making stages. 
Kako je poznato, miješalice se koriste za kućnu izradu sladoleda i normalno se sastoje od cilindrične zdjele s horizontalnom osi, u koju se nalijevaju sastojci za proizvodnju sladoleda zadane količine; od rashladne jedinice za hlađenje i održavanje zdjele i njenog sadržaja na temperaturi u opsegu od -10"C i -35%C; te od rotacionog članka za miješanje montiranog da rotira unutar zdjele i zamiješa sastojke u različitim fazama pravljenja sladoleda.
providing electrical stud welding equipment or another suitable welding current source, of which a first welding current connection (5) is electrically connected to the first metal plate and/or the second metal plate, and the electrical stud welding equipment being provided with a welding pin (7) to be connected with a second welding current connection (6), the welding pin having a cross section smaller than a cross section of the welding openings (4); 
– osiguravanju opreme za električno zavarivanje svornjaka ili drugog pogodnog izvora struje zavarivanja, gdje se prvi kontakt za ostvarivanje struje zavarivanja (5) električno spoji s prvom metalnom pločom i/ili drugom metalnom pločom, zatim se opremi doda zatik za zavarivanje (7) ili svornjak za zavarivanje, koje se nadalje navodi kao zatik za zavarivanje, koji treba spojiti s drugim kontaktom za ostvarivanje struje zavarivanja (6), gdje zatik ima poprečni presjek manji od poprečnog presjeka otvora za zavarivanje (4);
An air conditioning plant comprising: 
Postrojenje za klimatiziranje zraka, naznačeno time što se sastoji od:
The dosage form of any of claims 1 through 12, wherein the solid dispersion product comprises from 0.5 to 40% by weight of the pharmaceutically active ingredient, 40 to 97.5% by weight of said at least one pharmaceutically acceptable polymer, 2 to 20% by weight of said at least one solubilizer, and 0 to 15% by weight of additives. 
Oblik za doziranje u skladu s patentnim zahtjevom 1, naznačen time, da kruti disperzijski proizvod sadržava od oko 0,5 do 40 % težinskih udjela farmaceutski aktivnog sastojka, 40 do 97,5 % težinskih udjela navedenog barem jednog farmaceutski prihvatljivog polimera, 2 do 20 % težinskih udjela navedenog najmanje jednog solubilizatora i 0 do 15 % težinskih udjela aditiva.
In certain cases, a sample of the fluid flowing through the conduit is provided to a gas chromatograph coupled to the conduit (or the vessel). 
Uređaj prema bilo kojem od gornjih zahtjeva, naznačen time da je posuda (122) odvojivo spojena na ventil (118).
It is also known, e.g. from WO-A-02/064439 and WO-A-04/08317, to provide a pharmaceutical vial having a closure part made partly or wholly of thermoplastic elastomer material, and e.g. from WO-A-03/028785 to provide a hypodermic syringe having a plunger made partly of a thermoplastic elastomer material. 
Također je poznato, na primjer iz WO-A-02/064439 i WO-A-04/08317, da se proizvodi farmaceutska bočica koja ima element za zatvaranje koji je načinjen jednim dijelom od termoplastičnog elastomernog materijala, i, na primjer iz WO-A-03/028785, da se proizvodi potkožna šprica koja ima klip, koji je jednim dijelom načinjen od termoplastičnog elastomernog materijala.
Therefore, in one embodiment, a genetically modified mouse is provided, wherein the mouse comprises at an endogenous mouse MHC II locus a first nucleotide sequence encoding a chimeric human/mouse MHC II a polypeptide and a second nucleotide sequence encoding a chimeric human/mouse MHC II B polypeptide, wherein a human portion of the chimeric MHC II a polypeptide comprises an extracellular domain derived from an a polypeptide of a human HLA-DR4 protein and the human portion of the chimeric MHC II B polypeptide comprises an extracellular domain derived from a B polypeptide of a human HLA-DR4 protein, wherein a mouse portion of the chimeric MHC II a polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E a chain and a mouse portion of the chimeric MHC II B polypeptide comprises transmembrane and cytoplasmic domains of a mouse H-2E B chain, and wherein the mouse expresses a functional chimeric HLA-DR4/H-2E MHC II complex. 
Metoda izmjene mišjeg MHC II lokusa da izražava kimerni ljudski/mišji MHC II kompleks koji sadrži zamjenu mišjeg nukleotidnog slijeda koji kodira mišji MHC II nukleotidnim slijedom koji kodira kimerni ljudski/mišji MHC II kompleks na endogenom mišjem MHC II lokusu, pri čemu se nukleotidni slijed koji kodira kimerni ljudski/mišji MHC II kompleks sastoji od prvog nukleotidnog slijeda koji kodira domene al 1 a2 ljudskog MHC II a polipeptida 1 transmembranske 1 citoplazmatske domene mišjeg MHC II a polipeptida 1 drugog nukleotidnog slijeda koji kodira domene fB1 1 B2 ljudskog MHC II B polipeptida 1 transmembranske i citoplazmatske domene mišjeg MHC II f polipeptida, Metoda iz zahtjeva 11. gdje ljudske MHC II a odnosno (f: polipeptide kodiraju ljudski genski lanci a 1 B klase HLA II odabrani iz skupine koja se sastoji od genskih lanaca HLA-DR a1 f8,HLA-DQ a1B1iHLA-DP a1 f.
After stirring at 0 °C for 10 minutes, the reaction mixture is stirred at room temperature for 2.5 hours and then diluted with DCM (4 ml). 
Nakon miješanje 10 minuta pri O*C, reakcijsku smjesu se miješa 2,5 sata pri sobnoj temperaturi i zatim se razrijedi s DCM-om (4 ml).
Compounds of formula (IX) may in turn be prepared by reaction of compounds of formula (X) with compounds of formula (XI): 
Spojeve formule (IX) može se pak dobiti reakcijom spojeva formule (X) sa spojevima formule (XI):
The apparatus according to Claim 11, wherein the seal is a phase-change material or an aqueous membrane. 
Uređaj sukladno patentnom zahtjevu 8, naznačen time da je brtva (36) fazno promjenljivi materijal ili vodena membrana.
In some embodiments, the invention relates to an isolated polynucleotide comprising a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:40; SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76. 
HR P20151418 T1 PATENTNI ZAHTJEVI nos Humanizirano protutijelo anti-CD20 tipa II, naznačeno time, da obuhvaća sljedeće: varijabilno područje jakog lanca odabrano iz skupine koju čine SEQ ID NO:32 1 SEQ ID NO:40, 1 varijabilno područje KV1 slabog lanca od SEQ ID NO:76.
Alternatively, this reaction may be conveniently carried out in an aprotic solvent, such as dioxane or a dipolar aprotic solvent such as N,N -dimethylacetamide or acetonitrile in the presence of an acid, for example hydrogen chloride gas in diethyl ether or dioxane, or hydrochloric acid. 
Alternativno se ova reakcija može pikladno provesti u aprotičkom otapalu poput dioksana ili dipolarnom aprotičkom otapalu poput N,N-dimetilacetamida ili acetonitrila u prisutnosti kiseline, na primjer plinovitog klorovodika u dietileteru ili diokasnu, ili kloridnoj kiselini.
The method of claim 1 wherein the feedstock is removed from the pressurized pretreatment reactor using a hydrocyclone system or a sluice-type system. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se sirovinu ukloni iz reaktora za predobradu pod tlakom hidrociklonskim sustavom ili sustavom s branom.
Suitable alkanoyloxy and alkanoyl groups have from 2 to about 20 carbon atoms, more preferably from 2 to about 8 carbon atoms, still more preferably from 2 to about 6 carbon atoms, even more preferably 2 carbon atoms. 
Pogodne alkanoiloksi i alkanoil grupe imaju od 2 do oko 20 atoma ugljika, poželjnije od 2 do oko 8 atoma ugljika, još poželjnije od 2 do oko 6 atoma ugljika, čak poželjnije 2 atoma ugljika.
predisposing at least a target pressure or a target range of values for bringing the conditioning plant to a working level; 
zadavanja u najmanju ruku tlaka ili raspona vrijednosti radi dovođenja postrojenja za klimatiziranje na radnu razinu;
A method as claimed in claim 10 wherein the harvested roe is combined with an oil composition according to claim 6, or a fatty acid-containing fraction thereof, to influence taste. 
Postupak sukladno zahtjevu 10, naznačeno time, da se sakupljena ikra sjedinjuje sa sastavom ulja sukladno zahtjevu 6, ili njenom frakcijom koja sadrži masne kiseline radi uticaja na okus.
A composition for use according to claim 8 for treatment of a female patient above 65 years of age. 
Pripravak naznačen time da je za uporabu prema zahtjevu 8 u postupku koji sadrži:
According to another preferred embodiment of the inventive process, the at least one source of a water soluble lithium compound is added to the aqueous preparation in an amount such that the total amount of solubilised lithium in the aqueous preparation is from 1500 to 2500 ppm, calculated relative to the water in the preparation. According to the present invention, it is especially preferred that the aqueous preparation contains strains of bacteria selected from the group comprising Methylobacteria and Pseudomonas which are resistant to, tolerant to and/or degrade said aldehyde-releasing and/or aldehyde-based biocides in absence of said lithium ions, more preferably are strains of bacteria selected from the group comprising Methylobacteria extorquens, Pseudomonas putida, Pseudomonas mendocina or mixtures thereof, which are resistant to, tolerant to and/or degrade said aldehyde-releasing and/or aldehyde-based biocides in absence of said lithium ions. 
(b) barem jedan izvor u vodi topljivog spoja litija odabran iz skupine koju čine neorganske i/ili organske litijeve hidroksida, u količini tako da je ukupna količina otopljenog litija u vodenom pripravku od 1000 do 3000 ppm, izračunato u odnosu na težinu vode u pripravku; kao biocidnog pripravka u vodenom pripravku koji sadrži sojeve bakterija odabrane iz skupine koju čine Metilobacteria i Pseudomonas koje su rezistentne na, tolerantne na i/ili degradiraju biocide koji oslobađaju aldehid ifili biocide s jednom ili više aldehidnih skupina u odsutnosti litijevih iona.
A co-suspension according to claim 21, wherein at least one of the active agents included in the active agent particles is a highly potent active agent and the ratio of the total mass of the suspending particles to the total mass of the active agent particles is selected from between 5 and 175, between 10 and 150, between 15 and 125, and between 25 and 75. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 14, naznačen time što suspendirajuće čestice ostaju ko-locirane s česticama aktivnog sredstva čak i kada ih se podvrgava uzgonskim silama uvećanim centrifugiranjem uz ubrzanje koje se bira između ubrzanja od najmanje 1 g, najmanje 10 g, najmanje 50 g, te najmanje 100 g.
A system for remote metering the consumption of utilities distributed through a public distribution network of a plurality of consumers, the system comprising: 
Sustav za daljinsko mjerenje potrošnje komunalnih usluga distribuiranih putem javne distribucijske mreže (HV, MV, LV) za velik broj potrošača (H1, H2,..., Hn), pri čemu se sustav sastoji od
The antibody according to claim 1 or claim 2, wherein the antibody is a full-length antibody of an IgG1, IgG2, IgG3 or IgG4 isotype. 
Protutijelo sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje protutijelo je protutijelo pune dužine IgG1, IeG2, IgG3 ili IgG4 izotipa.
The depending claims develop further the central idea of the present invention. 
Ovisni patentni zahtjevi dalje razvijaju osnovnu ideju ovog izuma.
Volatiles were evaporated and the residue was purified directly on preparative TLC plate eluting with 7% MeOH/CH2Cl2 to give compound 4-1 (5 mg). 
Hlapive tvari se otpari, a ostatak pročisti izravno na ploči za preparativni TLC, uz eluiranje smjesom 7 % MeOH/CH>CI, kako bi se dobilo spoj 4-1 (5 mg).
isolating the compound of the Formula X by: 
izoliranja spoja sa formulom X pomoću:
In one embodiment the process is a process for enhancing production of virulence factors of the Bordetella species. 
(tii) povećavanja proizvodnje čimbenika virulentnosti 1z vrste iz roda Bordetella.
Moreover, many of them cannot be prepared in crystalline form at all because they form syrups containing variable quantity of water. 
Osim toga, mnoge od tih soli se uopće ne mogu proizvesti u kristaliničnom obliku, jer one tvore sirupe koji sadrže promjenljivu količinu vode.
The method of claim 1, wherein the active indicator substance comprises at least one UV indicator substance selected from the group consisting of flavonic acid, 4,4′-distyryl-biphenyls, stilbenes, pyrazolines, coumarin, dihydroquinolines, naphthalene acid imides, benzoaxazole, benzioxazole compounds, riboflavin, quinine, chlorogenic acid, quinoline yellow, and derivatives thereof. 
Mineralna vuna kao proizvod u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što mineralna vuna kao proizvod sadrži najmanje jednu UV-aktivnu komponentu, koju se bira iz skupine koju čine: flavonska kiselina, 4,4'-distirilbifenili, stilbeni, pirazolini, kumarin, dihidrokinolini, imidi naftalenske kiseline, benzoksazol, spojevi benzoksazola, riboflavin, kinin, klorogenska kiselina, kinolinsko žutilo i njegovi derivati.
A process according to claim 1 for the preparation of carvedilol form II, characterised by a melting point of 114 - 115 °C. 
6. Postupak prema patentnom zahtjevu 1 za pripremu karvedilola oblika II, naznačen time što je točka topljenja od
A glassy lozenge according to claim 17 wherein at least 60% of component (ii) consists of a non-crystallising form of sorbitol. 
Tableta-pastila prema patentnom zahtjevu 18, naznačena time, što se najmanje 60% komponente (1i) sastoji od nekristalizirajućeg oblika sorbitola.
The method of any one of claims 1-12, wherein the reaction of step c) is carried out in the presence of a solvent chosen from dimethylformamide, tetrahydrofuran, N-methyl-2-pyrrolidone, toluene, xylene, methyl tert- butyl ether, 2-methyltetrahydrofuran, diethyl ether, dimethyl sulfoxide, tert- butanol, and a mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1-12, naznačen time da se reakcija iz koraka c) provodi u prisutnosti otapala koje je odabrano od dimetilformamida, tetrahidrofurana, N-metil-2-pirolidona, toluena, ksilena, metil tert-butil etera, 2-metiltetrahidrofurana, dietil etera, dimetil sulfoksida, tert-butanol, te njihove smjese.
An inhibitor as claimed in claim 6 for use as in claim 1 wherein said medicament improves long term graft survival. 
Inhibitor u skladu s patentnim zahtjevom 6 za uporabu navedenu u patentnom zahtjevu 1 pri čemu navedeni medikament poboljšava dugoročno preživljavanje presatka.
A sliding bearing (110; 210; 310) according to claim 2, wherein said organic fillers are in the form of graphite in percentages ranging between 5 % and 30% by weight. 
Klizni ležaj (110; 210; 310) u skladu s patentnim zahtjevom 2, naznačen time, da su navedena organska punila u obliku grafita u postotcima u rasponu od 5% do 30% težinskog udjela.
In one embodiment, such a system comprises a bioreactor. 
U jednoj izvedbi, takav sustav obuhvaća bioreaktor.
In a further preferred embodiment, the medium comprises one or more amino acids. 
U slijedećem preporučenom sastavu, medij sadrži jednu ili više aminokiselina.
The antibody of 1, wherein the heavy chain comprises a heavy chain variable region having an amino acid sequence as set forth in SEQ ID NO: 10, or an antigen-binding or an immunologically functional immunoglobulin fragment thereof, and the light chain comprises a light chain variable region having an amino acid sequence as set forth in SEQ ID NO: 12, or an antigen-binding or an immunologically functional immunoglobulin fragment thereof. 
Antitijelo ili antigen vezujući fragment istog prema zahljevu 1, naznačen time da se teški lanac sastoji od varijabilne regije teškog lanca čiji je slijed SEQ ID NO: 10, a laki lanac se sastoji od varijabilne regije lakog lanca čiji je slijed SEQ ID NO: 12.
said liquid spraying component (240) performing spraying on the front part of said net's (230) outer surface not facing the chiller (100), contrariwise to the chiller (100) and to the incoming direction of air, 
- spomenuta komponenta (240) raspršivanja tekućine izvodi raspršivanje na prednjem dijelu spomenute mrežine (230) vanjske površine koja nije okrenuta prednjom stranom prema hladnjaku (100), u smjeru suprotnom kretanju kazaljke na satu u odnosu na hladnjak (100) i u odnosu na dolazni smjer zraka,
The method of claim 1, wherein the carbohydrate is present in an amount sufficient to inhibit the reaction of a free thiol on a first molecule of the GCB with a free thiol on a second molecule of the GCB to form an aggregate. 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za inhibiranje reakcije slobodnog tiola na prvoj molekuli proteina sa slobodnim tiolom na drugoj molekuli proteina kojom se formira agregat.
providing a bubble outlet (15) at or near the lower rear (17) side of the cavity (6) for allowing the bubbles to flow out from the mixing region along the bottom surface (3) towards the rear of the vessel. 
- < postavljanjem izlaza mjehurića (15) na ili blizu niže stražnje (17) strane šupljine (6) da mjehurići mogu otići iz područja miješanja duž površine dna (3) prema stražnjem dijelu plovila.
Isomers C and B are also either weakly active or inactive as inhibitors of the adrenergic receptors and this suggests that the compounds may lack the adrenergic side effects often encountered with tetrabenazine. 
Izomeri C i B su također ili slabo aktivni ili inaktivni kao inhibitori adrenergičkih receptora i to sugerira da spojevima mogu nedostajati adrenergička nuzdjelovanja često povezana s tetrabenazinom.
The properly substituted 1-bromo-phenylsulfanylbenzenes or 1-iodo-phenylsulfanylbenzenes were prepared from thiophenols IV and properly substituted aryliodides or aryl bromides according to the general procedures by Schopfer and Schlapbach Tetrahedron 2001, 57, 3069-3073; Bates et al. Org. Lett. 
Pravilno supstituirani 1-bromo-fenilsulfanilbenzeni ili 1-jodo-fenilsulfanilbenzeni pripravljeni su iz tiofenola IV 1 pravilno supstituiranih ariljodida ili arilbromida prema općem postupku kao kod Schopfer i Schlapbach Tetrahedron 2001., 57, 3069-3073; Bates I sur., Org, Lett.
A pharmaceutical tablet especially in accordance with the preceding items having (a) a cracking force of at least 110 N, preferably 120 N, more preferably 130 N, and even more preferably 140 N, when subjected to an indentation test; (b) a penetration depth to crack distance of at least 1.0 mm, preferably 1.2 mm, more preferably 1.4 mm, and even more preferably 1.6 mm, when subjected to an indentation test; and (c) capable of resisting a work of at least 0.06 J without cracking. 
Farmaceutska tableta prema prethodnim zahtjevima naznačena time da ima silu loma od najmanje 110 N, poželjno 120 N, poželjnije 130 N, te najpoželjnije 140 N, kada je podvrgnuta indentacijskom testu; (b) dubinu prodiranja s razmakom pukotine od najmanje 1.0 mm, poželjno 1.2 mm, poželjnije 1.4 mm, te najpoželjnije 1.6 mm, kada je podvrgnuta indentacijskom testu; te (c) da se može oduprijeti radu od najmanje 0.06 J bez loma.
The present invention also relates to the use of a combination or pharmaceutical composition as defined above for the treatment of a bacterial infection. 
Uporaba spoja za proizvodnju medikamenta za liječenje bakterijske infekcije, te je navedeni spoj, spoj sa Formulom
Surprisingly it has been found that compounds of formula (I) wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; 
R Pa % Noi x CH, naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i
(C1-C4 straight or branched chain alkyl)-C(O)-group. 
-C4 alkanoilna skupina ravnog ili razgranatog lanca.
increase of serum HDL cholesterol levels of at least 2%, at least 2.5%, at least, 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5% or at least 5.5% relative to a predose level upon administering to a subject a dose of 150 mg E2W; 
(b) povećanje razina HDL kolesterola u serumu od barem 2%, barem 2.5%, barem 3%, barem 3.5%, barem 4%, barem 4.5%, barem 5% ili barem 5.5% u odnosu na razinu prije doziranja nakon davanja subjektu doze od 150 mg E2W;
The refrigerant composition according to claim 1, which further comprises a stabilizer. 
Rashladni sastav prema zahtjevu 1, naznačen time, da nadalje sadrži stabilizator.